What is TransMedics?
Based in Andover, Massachusetts, TransMedics, Inc. is a pioneering medical device company dedicated to improving the viability of donor organs. The firm has developed a suite of portable perfusion systems, including the OCS Heart, OCS LUNG, and OCS Liver, which maintain organs in a near-physiologic, warm functioning state outside the human body. By bridging the gap between donor and recipient sites, TransMedics effectively mitigates the risks associated with traditional cold storage methods. The company's market position is defined by its ability to transform the standard of care in transplantation, enabling surgeons to perform procedures with greater precision and confidence across international markets, including Europe and Australia.
How much funding has TransMedics raised?
TransMedics has raised a total of $553.1M across 16 funding rounds:
Unspecified
$5.9M
Series F
$36M
Unspecified
$20M
Private Equity
$51.2M
Private Equity
$63.7M
Stock Offering
$104.7M
Stock Offering
$75M
Debt
$60M
Unspecified (2011): $5.9M featuring Undisclosed
Series F (2012): $36M backed by Hercules Capital Inc., Kleiner Perkins Caufield & Byers, Abrams Capital, and Flagship Pioneering
Unspecified (2015): $20M with participation from Undisclosed
Private Equity (2016): $51.2M led by BioStar Capital, Abrams Capital, InBio Ventures, KPCB, Lung Biotechnology PBC, Fayerweather Fund, Ervington Investments, and Flagship Ventures
Private Equity (2016): $63.7M supported by InBio Ventures, KPCB, Abrams Capital, Fayerweather Fund, BioStar Capital, Flagship Ventures, Lung Biotechnology PBC, and Ervington Investments
Stock Issuance/Offering (2019): $104.7M featuring Undisclosed
Stock Issuance/Offering (2020): $75M backed by Undisclosed
Debt (2022): $60M with participation from CIBC Innovation Banking
Key Investors in TransMedics
Kleiner Perkins
Kleiner Perkins is a Menlo Park-based venture capital firm that invests in early and growth-stage technology and life science companies, providing capital and operational support from seed through IPO.
Flagship Pioneering
Flagship Pioneering is a team of scientists and professionals that build companies designed to transform human health and sustainability through innovative scientific breakthroughs.
Abrams Capital
Abrams Capital employs a fundamental, value-oriented investment strategy, focusing on long-term horizons across a diverse spectrum of asset types and market sectors.
What's next for TransMedics?
With the support of major enterprise-level funding, TransMedics is well-positioned to scale its operational footprint and accelerate the adoption of its Organ Care System (OCS) platform. The company's strategic roadmap likely involves expanding its clinical reach and refining its perfusion monitoring systems to support a broader range of transplant applications. As the firm moves beyond its development and early-scaling phases, the focus will shift toward deepening market penetration and leveraging its robust intellectual property to maintain a competitive edge in the high-stakes medical device industry. Continued investment will be pivotal in sustaining the company's mission to increase the availability and quality of transplantable organs globally.
See full TransMedics company page
